Subscribe to this journal
Advanced Search
 array:22 [
  "pii" => "S2173572724002431"
  "issn" => "21735727"
  "doi" => "10.1016/j.medine.2024.10.002"
  "estado" => "S200"
  "fechaPublicacion" => "2024-10-25"
  "aid" => "2086"
  "copyright" => "Elsevier España, S.L.U. and SEMICYUC"
  "copyrightAnyo" => "2024"
  "documento" => "simple-article"
  "crossmark" => 0
  "subdocumento" => "cor"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:18 [
      "pii" => "S021056912400305X"
      "issn" => "02105691"
      "doi" => "10.1016/j.medin.2024.08.005"
      "estado" => "S200"
      "fechaPublicacion" => "2024-10-09"
      "aid" => "2086"
      "copyright" => "Elsevier España, S.L.U. y SEMICYUC"
      "documento" => "simple-article"
      "crossmark" => 0
      "subdocumento" => "cor"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Carta al Editor</span>"
        "titulo" => "Reversi&#243;n guiada de dabigatr&#225;n en un caso de shock hemorr&#225;gico masivo"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Guided reversal of dabigatran in massive hemorrhagic shock&#58; A case report"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 922
                "Ancho" => 3175
                "Tamanyo" => 274986
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Resultado de los test viscoel&#225;sticos &#40;ClotPro&#174;&#41; bajo los efectos de dabigatr&#225;n&#46; EX-test&#58; vista del proceso de coagulaci&#243;n tras la activaci&#243;n de la v&#237;a extr&#237;nseca&#46; IN-test&#58; prueba de cribado de la v&#237;a intr&#237;nseca de la coagulaci&#243;n&#46; FIB-test&#58; detecci&#243;n de fibrin&#243;geno funcional&#46; AP-test&#58; prueba EX-test con inhibici&#243;n de la fibrin&#243;lisis para confirmar la actividad hiperfibrinol&#237;tica&#46; HI-test&#58; prueba IN-test con adici&#243;n de heparinasa para confirmar la presencia de heparina&#46; ECA-test&#58; prueba espec&#237;fica para antagonistas directos de la trombina &#40;poco afectado por las heparinas o por antagonistas directos del factor X activado &#40;FXa&#41;&#46; RVV-test&#58; prueba espec&#237;fica para antagonistas directos del FXa&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A5 y A10&#58; amplitud a los 5 y 10 minutos tras el CT&#59; CFT&#58; tiempo de formaci&#243;n del co&#225;gulo&#59; CT&#58; tiempo de coagulaci&#243;n&#59; MCF&#58; firmeza m&#225;xima del co&#225;gulo&#59; &#40;mm&#41;&#58; amplitud del co&#225;gulo en mil&#237;metros&#59; &#40;s&#41;&#58; tiempo en segundos&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Manuel Fern&#225;ndez Caro, Manuel Casado&#95;M&#233;ndez, Francisco Javier Rodr&#237;guez Martorell, Antonio Manuel Puppo Moreno"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "Fern&#225;ndez Caro"
              ]
              1 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "Casado&#95;M&#233;ndez"
              ]
              2 => array:2 [
                "nombre" => "Francisco Javier"
                "apellidos" => "Rodr&#237;guez Martorell"
              ]
              3 => array:2 [
                "nombre" => "Antonio Manuel"
                "apellidos" => "Puppo Moreno"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2173572724002431"
          "doi" => "10.1016/j.medine.2024.10.002"
          "estado" => "S200"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173572724002431?idApp=WMIE"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S021056912400305X?idApp=WMIE"
      "url" => "/02105691/unassign/S021056912400305X/v1_202410091023/es/main.assets"
    ]
  ]
  "itemAnterior" => array:17 [
    "pii" => "S2173572724000274"
    "issn" => "21735727"
    "doi" => "10.1016/j.medine.2024.02.003"
    "estado" => "S200"
    "fechaPublicacion" => "2024-02-25"
    "aid" => "1976"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and SEMICYUC"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
      "titulo" => "Fractional excretion of sodium and potassium and urinary strong ion difference in the evaluation of persistent AKI in sepsis"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Excreci&#243;n fraccional de sodio y potasio&#44; y brecha ani&#243;nica urinaria en la evaluaci&#243;n de la IRA persistente en sepsis"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0010"
          "etiqueta" => "Figure 2"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr2.jpeg"
              "Alto" => 1448
              "Ancho" => 1675
              "Tamanyo" => 110835
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0135"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">ROC curve showing the area under de curve of FENa&#44; FEK and uSID&#46;</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">FENa&#58; fractional excretion of sodium&#59; FEK&#58; fractional excretion of potassium&#59; uSID&#58; urinary strong ion difference&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Nicol&#225;s Contrera Rol&#243;n, Joaqu&#237;n Cantos, Iv&#225;n Huespe, Eduardo Prado, Griselda I&#46; Bratti, Carlos Schreck, Sergio Giannasi, Guillermo Rosa Diez, Carlos F&#46; Varela"
          "autores" => array:9 [
            0 => array:2 [
              "nombre" => "Nicol&#225;s"
              "apellidos" => "Contrera Rol&#243;n"
            ]
            1 => array:2 [
              "nombre" => "Joaqu&#237;n"
              "apellidos" => "Cantos"
            ]
            2 => array:2 [
              "nombre" => "Iv&#225;n"
              "apellidos" => "Huespe"
            ]
            3 => array:2 [
              "nombre" => "Eduardo"
              "apellidos" => "Prado"
            ]
            4 => array:2 [
              "nombre" => "Griselda I&#46;"
              "apellidos" => "Bratti"
            ]
            5 => array:2 [
              "nombre" => "Carlos"
              "apellidos" => "Schreck"
            ]
            6 => array:2 [
              "nombre" => "Sergio"
              "apellidos" => "Giannasi"
            ]
            7 => array:2 [
              "nombre" => "Guillermo"
              "apellidos" => "Rosa Diez"
            ]
            8 => array:2 [
              "nombre" => "Carlos F&#46;"
              "apellidos" => "Varela"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173572724000274?idApp=WMIE"
    "url" => "/21735727/unassign/S2173572724000274/v1_202402251056/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
    "titulo" => "Guided reversal of dabigatran in massive hemorrhagic shock&#58; A case report"
    "tieneTextoCompleto" => true
    "saludo" => "Dear Editor&#58;"
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Manuel Fern&#225;ndez Caro, Manuel Casado M&#233;ndez, Francisco Javier Rodr&#237;guez Martorell, Antonio Manuel Puppo Moreno"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "Manuel"
            "apellidos" => "Fern&#225;ndez Caro"
            "email" => array:1 [
              0 => "mfercar@outlook.es"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "&#42;"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Manuel"
            "apellidos" => "Casado M&#233;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Francisco Javier"
            "apellidos" => "Rodr&#237;guez Martorell"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Antonio Manuel"
            "apellidos" => "Puppo Moreno"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "UGC de Cuidados Intensivos&#44; Hospital Universitario Virgen del Roc&#237;o&#44; Sevilla&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "UGC de Hematolog&#237;a&#44; Secci&#243;n de Hemostasia y Trombosis&#44; Hospital Universitario Virgen del Roc&#237;o&#44; Sevilla&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Reversi&#243;n guiada de dabigatr&#225;n en un caso de shock hemorr&#225;gico masivo"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 922
            "Ancho" => 3175
            "Tamanyo" => 283485
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Result of viscoelastic testing &#40;ClotPro&#174;&#41; under the effects of dabigatran&#46; <span class="elsevierStyleBold">EX-test</span>&#58; view of the coagulation process after activation of the extrinsic pathway&#46; <span class="elsevierStyleBold">IN-test</span>&#58; screening test of the intrinsic coagulation pathway&#46; <span class="elsevierStyleBold">FIB-test</span>&#58; detection of functional fibrinogen&#46; <span class="elsevierStyleBold">AP-test</span>&#58; EX-test with the inhibition of fibrinolysis to confirm hyper-fibrinolytic activity&#46; <span class="elsevierStyleBold">HI-test</span>&#58; IN-test with the addition of heparinase to confirm the presence of heparin&#46; <span class="elsevierStyleBold">ECA-test</span>&#58; specific test for direct thrombin antagonists &#40;scantly affected by heparins or direct activated factor X &#40;FXa&#41; antagonists&#41;&#46; <span class="elsevierStyleBold">RVV-test</span>&#58; specific test for direct FXa antagonists&#46; <span class="elsevierStyleBold">Parameters&#58;</span> CT&#58; clotting time&#59; A5 and A10&#58; amplitude 5 and 10&#8239;min after CT&#59; CFT&#58; clot formation time&#59; MCF&#58; maximum clot firmness&#46; Time in seconds &#40;s&#41;&#46; Clot size in millimeters &#40;mm&#41;&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Thromboembolic events are a major public health problem&#46; Current clinical practice guidelines preferentially recommend direct oral anticoagulants &#40;DOACs&#41; as the preferred choice for preventing or treating such events in patients with atrial fibrillation or venous thromboembolic disease&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Dabigatran&#44; a direct thrombin inhibitor&#44; is increasingly being used due to its advantages over vitamin K antagonists&#44; including a lower risk of intracranial bleeding&#44; fixed dosing without the need for laboratory monitoring or dietary restrictions&#44; few drug-drug interactions&#44; and a faster onset and offset of pharmacological effects&#44; which makes it easier to plan for invasive procedures&#46;<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Patients on DOACs may suffer severe bleeding or need urgent surgery and require a diagnosis with immediate treatment to reverse the anticoagulant effect&#46; As conventional tests take too long to provide results&#44; viscoelastic testing &#40;VET&#41;&#44; which is performed in whole blood and provides results in a few minutes&#44; could prove to be very useful if specific techniques for the detection of DOACs &#40;at levels &#62;50 ng&#47;mL&#41; based on activation with ecarin for anti-IIa &#40;ECA-test&#174;&#41; or with Russell viper venom for anti-Xa &#40;RVV&#8209;test&#174;&#41; are included&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">A 62-year-old woman was admitted to the hospital because of a reduced level of consciousness&#46; On arrival at the emergency department&#44; her blood pressure was 80&#47;55 mmHg&#44; and an endoscopy confirmed diffuse bleeding of the gastric mucosa&#44; with a hemoglobin concentration of 4 g&#47;dl on admission&#46; The VET-guided massive transfusion protocol for hemostatic resuscitation was activated&#44; with the transfusion of four units of packed red blood cells and 600 mL of plasma&#44; which failed to control the bleeding&#46; The patient was taking dabigatran at home&#44; so we decided to extend the study with a specific dabigatran test &#40;ECA-Test&#174;&#41;&#44; which confirmed a strong anticoagulant effect of the drug &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; We also measured specific dabigatran levels with the HemosIL&#174; test&#44; which showed a concentration 6 times higher than the upper reference limit &#40;1287 ng&#47;mL&#59; reference limit &#60; 200 ng&#47;mL&#41;&#46; The bleeding was finally controlled after three doses of idarucizumab each&#58; the first dose one hour after onset of the symptoms and the remaining doses every 1&#8211;2 h &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#44; followed by clinical improvement&#46; Despite bleeding control&#44; the patient died of nosocomial pneumonia after a torpid course in intensive care&#46; The RE&#8209;VERSE AD study concluded that idarucizumab&#44; a monoclonal antibody with high affinity and specificity for dabigatran&#44; quickly and effectively reverts the anticoagulant effect of the latter drug following a single dose&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Its use is rarely needed&#44; except in cases of potentially fatal bleeding or emergent surgery&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> However&#44; in the present case&#44; repeated dosing guided by laboratory tests proved necessary due to the overdosing of dabigatran&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">In conclusion&#44; specific VET provides high sensitivity and specificity in detecting the presence of dabigatran in blood&#44; justifying the use of antidotes&#44; although the use of specific quantitative tests in plasma allows more efficient guidance of administration&#44; as in our case&#44; where the drug was rapidly and specifically detected - confirming the causative agent and the need for idarucizumab&#46;</p><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Funding</span><p id="par0025" class="elsevierStylePara elsevierViewall">None&#46;</p></span><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Author contributions</span><p id="par0020" class="elsevierStylePara elsevierViewall">All the authors contributed to the study conception and design &#40;MFC&#44; MCM&#44; FJRM&#44; AMPM&#41;&#44; data acquisition &#40;MFC&#44; MCM&#44; FJRM&#41; or analysis and interpretation of the data &#40;MCM&#44; FJRM&#41;&#44; and critical review of the intellectual content &#40;MCM&#44; FJRM&#44; AMPM&#41;&#46; All the authors approved the final version of the manuscript submitted for publication&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Conflicts of interest</span><p id="par0030" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflict of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:5 [
        0 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Funding"
        ]
        1 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Author contributions"
        ]
        2 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Conflicts of interest"
        ]
        3 => array:2 [
          "identificador" => "xack784152"
          "titulo" => "Acknowledgements"
        ]
        4 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:2 [
      0 => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 922
            "Ancho" => 3175
            "Tamanyo" => 283485
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Result of viscoelastic testing &#40;ClotPro&#174;&#41; under the effects of dabigatran&#46; <span class="elsevierStyleBold">EX-test</span>&#58; view of the coagulation process after activation of the extrinsic pathway&#46; <span class="elsevierStyleBold">IN-test</span>&#58; screening test of the intrinsic coagulation pathway&#46; <span class="elsevierStyleBold">FIB-test</span>&#58; detection of functional fibrinogen&#46; <span class="elsevierStyleBold">AP-test</span>&#58; EX-test with the inhibition of fibrinolysis to confirm hyper-fibrinolytic activity&#46; <span class="elsevierStyleBold">HI-test</span>&#58; IN-test with the addition of heparinase to confirm the presence of heparin&#46; <span class="elsevierStyleBold">ECA-test</span>&#58; specific test for direct thrombin antagonists &#40;scantly affected by heparins or direct activated factor X &#40;FXa&#41; antagonists&#41;&#46; <span class="elsevierStyleBold">RVV-test</span>&#58; specific test for direct FXa antagonists&#46; <span class="elsevierStyleBold">Parameters&#58;</span> CT&#58; clotting time&#59; A5 and A10&#58; amplitude 5 and 10&#8239;min after CT&#59; CFT&#58; clot formation time&#59; MCF&#58; maximum clot firmness&#46; Time in seconds &#40;s&#41;&#46; Clot size in millimeters &#40;mm&#41;&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0010"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#40;&#35;&#41;&#58; The dabigatran levels in blood before the 1st dose of the antidote were not analyzed&#46; INR&#58; International normalized ratio&#46; APTT&#58; Activated partial thromboplastin time&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Variables&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Before 1st dose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Before 2nd dose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Before 3rd dose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">After 3rd dose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bleeding&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dabigatran &#40;ng&#47;mL&#41;&#40;30&#8211;225&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#35;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1287&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">269&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">APTT-ratio &#40;0&#46;75&#8211;1&#46;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;63&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;07&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;94&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">APTT &#40;s&#41;&#40;24&#46;8&#8211;37&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">143&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">126&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">105&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">INR&#40;0&#46;75&#8211;1&#46;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&#46;49&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;92&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;99&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;97&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3700960.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Evolution of massive bleeding and severe coagulopathy testing after repeated dosing of idarucizumab 5&#8239;g&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "When direct oral anticoagulants should not be standard treatment&#58; JACC state-of-the-art review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Bejjani"
                            1 => "C&#46;D&#46; Khairani"
                            2 => "A&#46; Assi"
                            3 => "G&#46; Piazza"
                            4 => "P&#46; Sadeghipour"
                            5 => "A&#46;H&#46; Talasaz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jacc.2023.10.038"
                      "Revista" => array:5 [
                        "tituloSerie" => "Am Coll Cardiol"
                        "fecha" => "2024"
                        "volumen" => "83"
                        "paginaInicial" => "444"
                        "paginaFinal" => "465"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety of dabigatran as an anticoagulant&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Y&#46; Zhou"
                            1 => "Z&#46; Yao"
                            2 => "L&#46; Zhu"
                            3 => "Y&#46; Tang"
                            4 => "J&#46; Chen"
                            5 => "J&#46; Wu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fphar.2021.626063; 626063"
                      "Revista" => array:3 [
                        "tituloSerie" => "Front Pharmacol"
                        "fecha" => "2021"
                        "volumen" => "12"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Oberladst&#228;tter"
                            1 => "W&#46; Voelckel"
                            2 => "C&#46; Schlimp"
                            3 => "J&#46; Zipperle"
                            4 => "B&#46; Ziegler"
                            5 => "O&#46; Grottke"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/anae.15254"
                      "Revista" => array:6 [
                        "tituloSerie" => "Anaesthesia"
                        "fecha" => "2021"
                        "volumen" => "76"
                        "paginaInicial" => "373"
                        "paginaFinal" => "380"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32946123"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Idarucizumab for dabigatran reversal - full cohort analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;V&#46; Pollack Jr&#46;"
                            1 => "P&#46;A&#46; Reilly"
                            2 => "J&#46; van Ryn"
                            3 => "J&#46;W&#46; Eikelboom"
                            4 => "S&#46; Glund"
                            5 => "R&#46;A&#46; Bernstein"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1707278"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2017"
                        "volumen" => "377"
                        "paginaInicial" => "431"
                        "paginaFinal" => "441"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28693366"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Multidisciplinary consensus document on the management of massive haemorrhage&#46; First update 2023 &#40;document HEMOMAS-II&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;V&#46; Llau"
                            1 => "C&#46; Aldecoa"
                            2 => "E&#46; Guasch"
                            3 => "P&#46; Marco"
                            4 => "P&#46; Marcos-Neira"
                            5 => "P&#46; Paniagua"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.medine.2023.05.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Med Intensiva &#40;Engl Ed&#41;"
                        "fecha" => "2023"
                        "volumen" => "47"
                        "paginaInicial" => "454"
                        "paginaFinal" => "467"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37536911"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack784152"
        "titulo" => "Acknowledgements"
        "texto" => "<p id="par0035" class="elsevierStylePara elsevierViewall">Thanks are due to Dr&#46; Jos&#233; Garnacho-Montero&#44; Dr&#46; &#193;ngel Herruzo-Avil&#233;s and Dr&#46; Esteban Fern&#225;ndez-Hinojosa for their contribution to the final review of the manuscript&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/21735727/unassign/S2173572724002431/v1_202410250423/en/main.assets"
  "Apartado" => null
  "PDF" => "https://static.elsevier.es/multimedia/21735727/unassign/S2173572724002431/v1_202410250423/en/main.pdf?idApp=WMIE&text.app=https://medintensiva.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173572724002431?idApp=WMIE"
]
Share
Articles in press Guided reversal of dabigatran in massive hemorrhagic shock: A case report
Journal Information
Previous article | Next article
Lee este artículo en Español
Export reference
Share
Share
Print
Download PDF
More article options
Statistics
Letter to the Editor
DOI: 10.1016/j.medine.2024.10.002
Available online 25 October 2024
Guided reversal of dabigatran in massive hemorrhagic shock: A case report
Reversión guiada de dabigatrán en un caso de shock hemorrágico masivo
Download PDF
Manuel Fernández Caroa,
Corresponding author
mfercar@outlook.es

Corresponding author.
, Manuel Casado Méndeza, Francisco Javier Rodríguez Martorellb, Antonio Manuel Puppo Morenoa
a UGC de Cuidados Intensivos, Hospital Universitario Virgen del Rocío, Sevilla, Spain
b UGC de Hematología, Sección de Hemostasia y Trombosis, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Evolution of massive bleeding and severe coagulopathy testing after repeated dosing of idarucizumab 5 g.

Article

These are the options to access the full texts of the publication Medicina Intensiva (English Edition)
Member of the society
Subscriber
Subscribe
Contact
Member
If you are a member of the Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias::
Go to the members area of the website of the SEMICYUC (www.semicyuc.org )and click the link to the magazine.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Intensiva (English Edition)

More information
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
atencionalcliente@elsevier.com

Subscribe to our newsletter

Recommended
articles
Challenges in the use of intravenous albumin in critically...
Med Intensiva. 2024;48:429-30
Critical bleeding-associated to DOACs...
Med Intensiva. 2023;47:733-5
Esophagogastric and portal pneumatosis secondary to severe...
Med Intensiva. 2023;47:562
Publish in
Medicina Intensiva
Free access articles
Clinical efficacy of oXiris-continuous hemofiltration...
10.1016/j.medine.2024.09.012
Impact of high-flow oxygen therapy via high velocity nasal...
10.1016/j.medine.2024.05.017
Incidence of venous thromboembolic disease and risk of...
10.1016/j.medine.2024.06.003
Multimedia
Complicated early prosthetic aortic valve infective endocarditis
More images.
Idiomas
Medicina Intensiva (English Edition)
Article options
Tools